Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)
Summary The Environmental Exposure Unit, an indoor pollen challenge system to test anti‐allergic medications, was used to compare the onset and duration of action and the efficacy of levocetirizine and desloratadine, two recently developed H1‐antagonists. In this double‐blind, placebo‐controlled, pa...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2004-02, Vol.58 (2), p.109-118 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118 |
|---|---|
| container_issue | 2 |
| container_start_page | 109 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 58 |
| creator | Day, J.H. Briscoe, M.P. Rafeiro, E. Ratz, J.D. |
| description | Summary
The Environmental Exposure Unit, an indoor pollen challenge system to test anti‐allergic medications, was used to compare the onset and duration of action and the efficacy of levocetirizine and desloratadine, two recently developed H1‐antagonists. In this double‐blind, placebo‐controlled, parallel‐group study, qualified subjects were randomised to once‐daily levocetirizine 5 mg (n = 141), desloratadine 5 mg (n = 140) or placebo (n = 92) and exposed to ragweed pollen on two consecutive days (7 h and 6 h). Symptoms were self‐rated every 30 min. On both days, levocetirizine produced a greater improvement in the major symptom complex score (primary efficacy variable) than desloratadine (p = 0.015); both were better than placebo (p |
| doi_str_mv | 10.1111/j.1368-5031.2004.0117.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71793602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71793602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4487-908ea6a58ad7ddb0bb2abaa7160a855d5b46e2eca292c5c50a631e7c4d7fab2c3</originalsourceid><addsrcrecordid>eNpNksGO0zAQhiMEYpeFVwBfQCCRYidxnEhcUBWWRStYoa04WhNnwrokdrGd0vKGvBWO2gK-zK_x989IM5MkzxhdsPjerBcsL6uU05wtMkqLBWVMLHb3knMmiixlWcHuR31izpJH3q8pzTiv6MPkjHEaFS_Pk99LO27AQdBbJGrQRisYCPZ9jGr_mljjMRAwHemmmbKG2J6AOqkBt1Zh0E7_0gYPIPrBRha6OdNbR_x-3AQ7-tngEbw1sQcMA7pvWhF3F7sG7Yk2xE_tGlXwBLcwTBCwm7PhDkljttpZM6IJ0dzsNtZPDskqWsnLplm9epw86GHw-OQYL5LV--Z2-SG9_nx5tXx3naqiqERa0wqhBF5BJ7qupW2bQQsgWEmh4rzjbVFihgqyOlNccQplzlCoohM9tJnKL5IXh7obZ39M6IMctVc4DGDQTl4KJuq8pFkEnx7BqR2xkxunR3B7eRp-BJ4fAfBx6r0Do7T_j-N1TWsWubcH7qcecP_vn8r5FuRaznuW857lfAtyvgW5k1cflzdRRXt6sGsfcPfXDu67LEUuuPz66VKWvL69-SKY5Pkfn6C72Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71793602</pqid></control><display><type>article</type><title>Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Day, J.H. ; Briscoe, M.P. ; Rafeiro, E. ; Ratz, J.D.</creator><creatorcontrib>Day, J.H. ; Briscoe, M.P. ; Rafeiro, E. ; Ratz, J.D.</creatorcontrib><description>Summary
The Environmental Exposure Unit, an indoor pollen challenge system to test anti‐allergic medications, was used to compare the onset and duration of action and the efficacy of levocetirizine and desloratadine, two recently developed H1‐antagonists. In this double‐blind, placebo‐controlled, parallel‐group study, qualified subjects were randomised to once‐daily levocetirizine 5 mg (n = 141), desloratadine 5 mg (n = 140) or placebo (n = 92) and exposed to ragweed pollen on two consecutive days (7 h and 6 h). Symptoms were self‐rated every 30 min. On both days, levocetirizine produced a greater improvement in the major symptom complex score (primary efficacy variable) than desloratadine (p = 0.015); both were better than placebo (p < 0.001). Levocetirizine acted earlier (1 h vs. 3 h) and produced greater symptom relief at 24 h than desloratadine (p = 0.003). Levocetirizine also alleviated nasal obstruction better than desloratadine (p = 0.007) on day 1; and better than placebo (p = 0.014) after the second dose on day 2, which was not observed with desloratadine. Levocetirizine and desloratadine were safe and well tolerated.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/j.1368-5031.2004.0117.x</identifier><identifier>PMID: 15055856</identifier><language>eng</language><publisher>Oxford, UK; Malden, USA: Blackwell Science Ltd</publisher><subject>Adolescent ; Adult ; Allergic rhinitis ; antihistamine ; Biological and medical sciences ; Cetirizine - therapeutic use ; clinical trial ; Cohort Studies ; comparison ; desloratadine ; Double-Blind Method ; EEU ; efficacy ; Female ; General aspects ; hay fever ; Histamine H1 Antagonists, Non-Sedating - therapeutic use ; Humans ; levocetirizine ; Loratadine - analogs & derivatives ; Loratadine - therapeutic use ; Male ; Medical sciences ; nasal congestion ; Non tumoral diseases ; Otorhinolaryngology. Stomatology ; Piperazines - therapeutic use ; Rhinitis, Allergic, Seasonal - drug therapy ; Severity of Illness Index ; Treatment Outcome ; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><ispartof>International journal of clinical practice (Esher), 2004-02, Vol.58 (2), p.109-118</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4487-908ea6a58ad7ddb0bb2abaa7160a855d5b46e2eca292c5c50a631e7c4d7fab2c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1368-5031.2004.0117.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1368-5031.2004.0117.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15599091$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15055856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Day, J.H.</creatorcontrib><creatorcontrib>Briscoe, M.P.</creatorcontrib><creatorcontrib>Rafeiro, E.</creatorcontrib><creatorcontrib>Ratz, J.D.</creatorcontrib><title>Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Summary
The Environmental Exposure Unit, an indoor pollen challenge system to test anti‐allergic medications, was used to compare the onset and duration of action and the efficacy of levocetirizine and desloratadine, two recently developed H1‐antagonists. In this double‐blind, placebo‐controlled, parallel‐group study, qualified subjects were randomised to once‐daily levocetirizine 5 mg (n = 141), desloratadine 5 mg (n = 140) or placebo (n = 92) and exposed to ragweed pollen on two consecutive days (7 h and 6 h). Symptoms were self‐rated every 30 min. On both days, levocetirizine produced a greater improvement in the major symptom complex score (primary efficacy variable) than desloratadine (p = 0.015); both were better than placebo (p < 0.001). Levocetirizine acted earlier (1 h vs. 3 h) and produced greater symptom relief at 24 h than desloratadine (p = 0.003). Levocetirizine also alleviated nasal obstruction better than desloratadine (p = 0.007) on day 1; and better than placebo (p = 0.014) after the second dose on day 2, which was not observed with desloratadine. Levocetirizine and desloratadine were safe and well tolerated.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Allergic rhinitis</subject><subject>antihistamine</subject><subject>Biological and medical sciences</subject><subject>Cetirizine - therapeutic use</subject><subject>clinical trial</subject><subject>Cohort Studies</subject><subject>comparison</subject><subject>desloratadine</subject><subject>Double-Blind Method</subject><subject>EEU</subject><subject>efficacy</subject><subject>Female</subject><subject>General aspects</subject><subject>hay fever</subject><subject>Histamine H1 Antagonists, Non-Sedating - therapeutic use</subject><subject>Humans</subject><subject>levocetirizine</subject><subject>Loratadine - analogs & derivatives</subject><subject>Loratadine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>nasal congestion</subject><subject>Non tumoral diseases</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Piperazines - therapeutic use</subject><subject>Rhinitis, Allergic, Seasonal - drug therapy</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNksGO0zAQhiMEYpeFVwBfQCCRYidxnEhcUBWWRStYoa04WhNnwrokdrGd0vKGvBWO2gK-zK_x989IM5MkzxhdsPjerBcsL6uU05wtMkqLBWVMLHb3knMmiixlWcHuR31izpJH3q8pzTiv6MPkjHEaFS_Pk99LO27AQdBbJGrQRisYCPZ9jGr_mljjMRAwHemmmbKG2J6AOqkBt1Zh0E7_0gYPIPrBRha6OdNbR_x-3AQ7-tngEbw1sQcMA7pvWhF3F7sG7Yk2xE_tGlXwBLcwTBCwm7PhDkljttpZM6IJ0dzsNtZPDskqWsnLplm9epw86GHw-OQYL5LV--Z2-SG9_nx5tXx3naqiqERa0wqhBF5BJ7qupW2bQQsgWEmh4rzjbVFihgqyOlNccQplzlCoohM9tJnKL5IXh7obZ39M6IMctVc4DGDQTl4KJuq8pFkEnx7BqR2xkxunR3B7eRp-BJ4fAfBx6r0Do7T_j-N1TWsWubcH7qcecP_vn8r5FuRaznuW857lfAtyvgW5k1cflzdRRXt6sGsfcPfXDu67LEUuuPz66VKWvL69-SKY5Pkfn6C72Q</recordid><startdate>200402</startdate><enddate>200402</enddate><creator>Day, J.H.</creator><creator>Briscoe, M.P.</creator><creator>Rafeiro, E.</creator><creator>Ratz, J.D.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200402</creationdate><title>Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)</title><author>Day, J.H. ; Briscoe, M.P. ; Rafeiro, E. ; Ratz, J.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4487-908ea6a58ad7ddb0bb2abaa7160a855d5b46e2eca292c5c50a631e7c4d7fab2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Allergic rhinitis</topic><topic>antihistamine</topic><topic>Biological and medical sciences</topic><topic>Cetirizine - therapeutic use</topic><topic>clinical trial</topic><topic>Cohort Studies</topic><topic>comparison</topic><topic>desloratadine</topic><topic>Double-Blind Method</topic><topic>EEU</topic><topic>efficacy</topic><topic>Female</topic><topic>General aspects</topic><topic>hay fever</topic><topic>Histamine H1 Antagonists, Non-Sedating - therapeutic use</topic><topic>Humans</topic><topic>levocetirizine</topic><topic>Loratadine - analogs & derivatives</topic><topic>Loratadine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>nasal congestion</topic><topic>Non tumoral diseases</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Piperazines - therapeutic use</topic><topic>Rhinitis, Allergic, Seasonal - drug therapy</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Day, J.H.</creatorcontrib><creatorcontrib>Briscoe, M.P.</creatorcontrib><creatorcontrib>Rafeiro, E.</creatorcontrib><creatorcontrib>Ratz, J.D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Day, J.H.</au><au>Briscoe, M.P.</au><au>Rafeiro, E.</au><au>Ratz, J.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2004-02</date><risdate>2004</risdate><volume>58</volume><issue>2</issue><spage>109</spage><epage>118</epage><pages>109-118</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Summary
The Environmental Exposure Unit, an indoor pollen challenge system to test anti‐allergic medications, was used to compare the onset and duration of action and the efficacy of levocetirizine and desloratadine, two recently developed H1‐antagonists. In this double‐blind, placebo‐controlled, parallel‐group study, qualified subjects were randomised to once‐daily levocetirizine 5 mg (n = 141), desloratadine 5 mg (n = 140) or placebo (n = 92) and exposed to ragweed pollen on two consecutive days (7 h and 6 h). Symptoms were self‐rated every 30 min. On both days, levocetirizine produced a greater improvement in the major symptom complex score (primary efficacy variable) than desloratadine (p = 0.015); both were better than placebo (p < 0.001). Levocetirizine acted earlier (1 h vs. 3 h) and produced greater symptom relief at 24 h than desloratadine (p = 0.003). Levocetirizine also alleviated nasal obstruction better than desloratadine (p = 0.007) on day 1; and better than placebo (p = 0.014) after the second dose on day 2, which was not observed with desloratadine. Levocetirizine and desloratadine were safe and well tolerated.</abstract><cop>Oxford, UK; Malden, USA</cop><pub>Blackwell Science Ltd</pub><pmid>15055856</pmid><doi>10.1111/j.1368-5031.2004.0117.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2004-02, Vol.58 (2), p.109-118 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71793602 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Allergic rhinitis antihistamine Biological and medical sciences Cetirizine - therapeutic use clinical trial Cohort Studies comparison desloratadine Double-Blind Method EEU efficacy Female General aspects hay fever Histamine H1 Antagonists, Non-Sedating - therapeutic use Humans levocetirizine Loratadine - analogs & derivatives Loratadine - therapeutic use Male Medical sciences nasal congestion Non tumoral diseases Otorhinolaryngology. Stomatology Piperazines - therapeutic use Rhinitis, Allergic, Seasonal - drug therapy Severity of Illness Index Treatment Outcome Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| title | Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A46%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20clinical%20efficacy,%20onset%20and%20duration%20of%20action%20of%20levocetirizine%20and%20desloratadine%20for%20symptoms%20of%20seasonal%20allergic%20rhinitis%20in%20subjects%20evaluated%20in%20the%20Environmental%20Exposure%20Unit%20(EEU)&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Day,%20J.H.&rft.date=2004-02&rft.volume=58&rft.issue=2&rft.spage=109&rft.epage=118&rft.pages=109-118&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/j.1368-5031.2004.0117.x&rft_dat=%3Cproquest_pubme%3E71793602%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71793602&rft_id=info:pmid/15055856&rfr_iscdi=true |